CAAS Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

CAAS Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,000	Closed	-$204K	–	903
2022 Q4	$204K	Sell	20,000 -65,851	-77%	-$438K	0.01%	611
2022 Q3	$213K	Sell	85,851 -11,661	-12%	-$43.3K	0.01%	629
2022 Q2	$242K	Buy	97,512 +11,661	+14%	+$23.3K	0.01%	642
2022 Q1	$255K	Hold	85,851	–	–	0.01%	440
2021 Q4	$607K	Hold	85,851	–	–	0.01%	513
2021 Q3	$895K	Buy	85,851 +65,404	+320%	+$679K	0.02%	519
2021 Q2	$251K	Sell	20,447 -329,553	-94%	-$5.61M	﹤0.01%	843
2021 Q1	$7.7M	Buy	+350,000	New	+$7.67M	0.08%	265

Other funds holding TERN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAAS Capital Management's TERN Position: Q1 2023 in Review

CAAS Capital Management sold out of Terns Pharmaceuticals (TERN) in Q1 2023, closing a stake of 20,000 shares — an estimated $204K sold.

CAAS Capital Management first reported a position in TERN in Q1 2021 and held it in 8 quarters. The position peaked at $7.7M in Q1 2021. 78 funds tracked by Wall St. Rank hold TERN as of Q1 2023.

CAAS Capital Management reported no remaining Terns Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 20,000 Terns Pharmaceuticals shares in Q1 2023, an estimated $204K.
CAAS Capital Management first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 8 quarters.
CAAS Capital Management's Terns Pharmaceuticals position peaked at $7.7M in Q1 2021.
78 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.